Kinarus Therapeutics Holding AG (XSWX:KNRS) EBIT : CHF-0.13 Mil (TTM As of Dec. 2021)

View and export this data going back to 1999. Start your Free Trial

What is Kinarus Therapeutics Holding AG EBIT?

Kinarus Therapeutics Holding AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2021 was CHF-0.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2021 was CHF-0.13 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kinarus Therapeutics Holding AG's annualized ROC % for the quarter that ended in Dec. 2021 was -460.69%. Kinarus Therapeutics Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kinarus Therapeutics Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -2.83%.

Kinarus Therapeutics Holding AG EBIT Historical Data

The historical data trend for Kinarus Therapeutics Holding AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kinarus Therapeutics Holding AG EBIT Chart

Kinarus Therapeutics Holding AG Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

-0.47

-0.77

-0.89

-0.13

Kinarus Therapeutics Holding AG Semi-Annual Data
	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
EBIT	Get a 7-Day Free Trial															-0.30	0.19	-0.19	0.04	-0.17

Competitive Comparison of Kinarus Therapeutics Holding AG's EBIT

For the Airports & Air Services subindustry, Kinarus Therapeutics Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kinarus Therapeutics Holding AG's EV-to-EBIT Distribution in the Transportation Industry

For the Transportation industry and Industrials sector, Kinarus Therapeutics Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kinarus Therapeutics Holding AG's EV-to-EBIT falls into.

Kinarus Therapeutics Holding AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.13 Mil.

Kinarus Therapeutics Holding AG (XSWX:KNRS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kinarus Therapeutics Holding AG's annualized ROC % for the quarter that ended in Dec. 2021 is calculated as:

	ROC % (Q: Dec. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2021 )	+	Invested Capital (Q: Dec. 2021 ))	/ count )
=	-0.334 * ( 1 - 0% )	/	( (0.124	+	0.021)	/ 2 )
=	-0.334	/	0.0725
=	-460.69 %

where

	Invested Capital		(Q: Jun. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.181	-	0.046	-	( 0.17	-	max(0, 0.17	-	0.181	+	0.17	))
=	0.124

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.136	-	0.086	-	( 0.124	-	max(0, 0.107	-	0.136	+	0.124	))
=	0.021

Note: The Operating Income data used here is two times the semi-annual (Dec. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Kinarus Therapeutics Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2021 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2021		Q: Dec. 2021
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.334	/	( ( (0 + max(-0.159, 0))	+	(0 + max(-0.095, 0)) )	/	2 )
=	-0.334	/	( ( 0	+	0 )	/	2 )
=	-0.334	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.011)	-	(0.046	+	0	+	0.124)
=	-0.159

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.012)	-	(0.086	+	0	+	0.021)
=	-0.095

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kinarus Therapeutics Holding AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2021 )
	=	-0.13	/	4.596
	=	-2.83 %

Kinarus Therapeutics Holding AG EBIT Related Terms

Thank you for viewing the detailed overview of Kinarus Therapeutics Holding AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Kinarus Therapeutics Holding AG (XSWX:KNRS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Transportation » Kinarus Therapeutics Holding AG (XSWX:KNRS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3, Avenue de Florimont, Lausanne, CHE, CH-1006

Website

https://www.perfect.aero

Perfect Holding SA is a Switzerland-based company that focuses on the acquisition and management of investments in companies, which are active in the aircraft management and related services sector. The company operates in one business segment which includes Charters. The products provided by the company include Aircraft sales, Charter sales, and Aircraft consultancy.

Kinarus Therapeutics Holding AG (XSWX:KNRS) Headlines

No Headlines